top of page

The potential of Tasquinimod in the treatment of advanced Myeloproliferative Neoplasms (MPNs): A look into the future

Updated: Feb 15, 2024

Before delving into the details of the study, it is important to understand what Myeloproliferative Neoplasms (MPN) are. MPNs are rare types of blood cancers that arise from excessive production of red blood cells, platelets or white blood cells in the bone marrow. 



Focusing on the clinical study, Dr. Warren Fiskus, a well-known specialist in the field of hematology, recently presented promising research results at the 23rd annual meeting of the American Society of Hematology (ASH23).


Content guide



Understanding Myeloproliferative Neoplasms (MPNs)


The main subtypes of MPNs are Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Each of these types of MPN presents its own unique challenges. Myelofibrosis is a particularly severe condition that results in the development of fibrous tissue in the bone marrow, like scars in the marrow, which impairs normal blood cell production. The severity of MPNs is classified as low, intermediate or high risk, according to the various scales of the International Prognostic Scoring System.



Dr. Warren Fiskus' Promising Research at ASH23


Focusing on the clinical study, Dr. Warren Fiskus, a well-known specialist in the field of hematology, recently presented promising research results at the 23rd annual meeting of the American Society of Hematology (ASH23).


In his study, Dr. Fiskus presents tasquinimod, a minute compound recognized for its ability to inhibit tumor expansion.


The efficacy of this compound was explored in preclinical models of advanced MPNs, using mice implanted with human cells. The results were promising and suggest that tasquinimod could represent a feasible treatment option for some cases of MPN.


The research is in its early stages but this could represent a substantial advance in the search for effective therapies for these diseases. Further research is needed to evaluate the safety, tolerability and efficacy of the drug in a broader population. In addition, further research is needed to determine the optimal methods for integrating tasquinimod into the existing treatment landscape. This could involve employing the drug as a stand-alone therapy or in conjunction with other existing drugs.


Overall, the findings of Dr. Fiskus' study at ASH23 could bring hope to patients facing advanced MPN. While much remains to be done, the potential of tasquinimod offers a new avenue of exploration in the effort to eradicate cancer.


Focusing on the clinical study, Dr. Warren Fiskus, a well-known specialist in the field of hematology, recently presented promising research results at the 23rd annual meeting of the American Society of Hematology (ASH23).

Source: Medriva



References

Medriva. (s.f.). The Potential of Tasquinimod in Treating Advanced Myeloproliferative Neoplasms: A Glimpse into the Future. https://medriva.com/cancer/the-potential-of-tasquinimod-in-treating-advanced-myeloproliferative-neoplasms-a-glimpse-into-the-future/


MD Anderson. (2023). MD Anderson Research Highlights: ASH 2023 Special Edition. https://www.mdanderson.org/newsroom/md-anderson-research-highlights–ash-2023-special-edition.h00-159624168.html


American Society of Hematology (ASH). (2023). 741 Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase. https://ash.confex.com/ash/2023/webprogram/Paper185031.html

50 views0 comments

Comentarios

Obtuvo 0 de 5 estrellas.
Aún no hay calificaciones

Agrega una calificación
Global MPN Scientific Foundation Logo

Contact

Avenida Josep Tarradellas 157, 5o 2a - Barcelona, 08029 - Spain

Follow

Sign up to get the latest news on our activities and MPN news.

Thanks for subscribing!

CONTENT TRANSLATION DISCLAIMER

Please note that this website uses AI to automatically translate its content to other languages, to help people to better understand the content that we originally publish in English. While we have made every effort to ensure the accuracy of the translation, there may be some mistakes or inaccuracies. We apologize for any errors and suggest visiting the original text in English for the most accurate information.

MEDICAL DISCLAIMER

Information on this website is provided for informational purposes only and is not intended as a substitute for the advice provided by your physician or other healthcare professional. You should not use the information on this website for diagnosing or treating a health problem or disease, or prescribing any medication or other treatment.

 

Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment. Nothing contained on this website is intended to be for medical diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider. Should you have any healthcare-related questions, please call or see your physician or other qualified healthcare provider promptly. Always consult with your physician or other qualified healthcare provider before embarking on a new treatment, diet, or fitness program. 

This website does not recommend self-management of health issues. Information obtained by using this website is not exhaustive and does not cover all diseases, ailments, physical conditions, or their treatment. Should you have any healthcare-related questions, please call or see your physician or other qualified healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.

bottom of page